Yayın:
Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer

Küçük Resim

Akademik Birimler

Kurum Yazarları

Canhoroz, Mustafa
Ölmez, Ömer Fatih
Kanat, Özkan
Kurt, Ender
Erol, Muharrem
Yorulmaz, Nadide

Yazarlar

Çubukcu, Erdem
Canhoroz, Mustafa
Ölmez, Ömer Fatih
Kanat, Özkan
Kurt, Ender
Erol, Muharrem
Çubukcu, Sinem
Yorulmaz, Nadide
Bayram, Sami
Evrensel, Türkkan

Danışman

Dil

Türü

Yayıncı:

Derman Medical Publ

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Özet

Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.

Açıklama

Kaynak:

Anahtar Kelimeler:

Konusu

Nonsmall cell lung cancer, Adjuvant chemotherapy, Cisplatin, General & internal medicine

Alıntı

Endorsement

Review

Supplemented By

Referenced By

3

Views

20

Downloads

View PlumX Details